Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Authors
Srđan Verstovšek•Ruben Mesa•Hagop Kantarjian
Journal
Haematologica
Published
January 23, 2015
100%
Supporters
Support the authors with ResearchCoin
Topics
DOI
License
cc-by-nc